权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Core B. Clinical Translational Core

核心 B. 临床转化核心

基本信息

批准号：
10682398
负责人：
Sally Ozonoff
金额：
$ 32.45万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-21 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10682398
关键词：
Address Age Behavioral Biological California Characteristics Childhood Clinical Clinical Trials Collection DiGeorge Syndrome Diagnostic Dimensions Disease Doctor of Philosophy Down Syndrome Economics Ensure Ethnic Origin Evaluation Failure Fragile X Syndrome Funding Genetic Genomic medicine Genomics Health Health Technology Heterogeneity Human Incentives Individual Infrastructure Intellectual and Developmental Disabilities Research Centers Investigation Learning Libraries Link Maps Measures Methodology Molecular Analysis Monitor Mood Disorders Names National Institute of Child Health and Human Development Participant Patient Recruitments Phenotype Population Process Productivity Qualifying Race Registries Research Research Personnel Resources Science Scientist Services Site Standardization Symptoms Syndrome Technology Testing Training Translations Universities Variant Venous blood sampling autism spectrum disorder biobehavior clinical translation community engagement comorbidity comparison group cost cost effective treatment cost effectiveness design experience improved inclusion criteria innovation instrument interest neurobehavioral neuropathology patient engagement programs psychologic recruit standardize measure telehealth tool

项目摘要

PROJECT SUMMARY – CLINICAL TRANSLATIONAL CORE The present application seeks funding to continue the MIND Institute Intellectual and Developmental Disabilities Research Center (IDDRC) at the University of California, Davis. The IDDRC was launched in 2013 and is the newest of the 14 IDDRCs in the network. The Clinical Translational Core (CTC) is designed to establish and maintain an operational framework that is optimal for recruitment, diagnostic assessment, neurobehavioral characterization, and mapping of phenotypes to underlying biological mechanisms for a diverse range of clinical populations. The CTC will address five specific aims. Aim 1 is to enhance recruitment of a diverse range of participants. This aim will be met through systematic community engagement and a growing participant registry that includes multiple ethnicities, races, and economic backgrounds with both atypical and typical populations across a wide age span. Aim 2 is to provide behavioral and diagnostic characterization of human participants. This aim will be met by providing access to experienced clinicians who can conduct specialized evaluations, advise studies in best practices, provide training in administration of standardized measures, establish initial reliability, and monitor administration fidelity, as well as by providing access to specialized testing space and connect investigators with clinical trials expertise. Aim 3 is to provide access to state-of-the-art “deep phenotyping” tools and expertise in genomics. This aim will be met by offering tools and training to enhance phenotypic characterization of participants, making available recent innovations in deep phenotyping and genomics to IDDRC investigators. Aim 4 is to support the integration of technology into research, especially telehealth methodologies that can lead to scalable, accessible, and cost-effective treatments for IDD conditions. This aim will be met by providing on-site high-level research IT support and access to the full array of technologies and expertise at UC Davis Health. Aim 5 is to facilitate collection and analysis of biospecimens from human participants and promote sharing across IDDRC projects. This aim will be met by providing phlebotomy services and access and incentives to use a core-managed freezer library for biospecimen storage as well as by links to the MIND IDDRC Biological and Molecular Analysis Core and the MIND Institute Genomic Medicine Program. The proposed CTC has been significantly expanded relative to the previous funding period, with the most significant change being the integration of the deep phenotyping and measure dissemination functions of the previous Neurobehavioral Analysis Core, which has led us to rename this expanded core, the CTCx. The Director of the CTC is Sally Ozonoff, PhD.

项目总结-临床转化核心